Hims & Hers Health (NYSE: HIMS) shares fell about 4% to $22.09 in premarket trading on Tuesday after the telehealth company reported a third-quarter net loss, lowered its full-year profit forecast, and warned that subscriber weakness could continue into the fourth quarter. The company reduced its 2026 adjusted EBITDA guidance to $257 million–$277 million from $275 million–$325 million.
Visit Website